Actinic (Solar) Keratosis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Actinic (Solar) Keratosis – Drugs In Development, 2024 report and make more profitable business decisions.
An actinic keratosis, also known as a solar keratosis, is a scaly or crusty growth (lesion). It most often appears on the bald scalp, face, ears, lips, backs of the hands and forearms, shoulders, neck, or any other areas of the body frequently exposed to the sun. The signs and symptoms of an actinic keratosis include a hard, wart-like surface, patch or bump on the top layer of skin, itching or burning in the affected area, and color as varied as pink, red or brown, or flesh-colored. The predisposing factors include age, sunny climate, history of frequent or intense sun exposure or sunburn, pale skin, red or blond hair, blue or light-colored eyes, and a weak immune system as a result of chemotherapy, chronic leukemia, AIDS, or organ transplant medications.
The Actinic (Solar) Keratosis drugs in development market research report provide comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Actinic (Solar) Keratosis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 24 molecules, with 24 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Actinic (Solar) Keratosis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Actinic (Solar) Keratosis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Actinic (Solar) Keratosis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Biofrontera AGClaradele Pharmaceuticals Inc
Coegin Pharma AB
DFB Soria LLC
Enkang Pharmaceutical Technology (Guangzhou) Co Ltd
G&E Herbal Biotechnology Co.
Ltd.
Ingenew Pharmaceuticals Inc
Invion Ltd
Laboratories Ojer Pharma SL
Maruho Co Ltd
MedC Biopharma Ltd
MediWound Ltd
Mustafa Nevzat Ilac ve Kimyevi Maddeler San Tic AS
N1 Life Inc
Neonc Technologies Inc
Oncology Research International Ltd
PharmaEssentia Corp
PharmaEssentia Japan KK
Phd Skin Care LLC
Ponce Therapeutics Inc
RepoCeuticals ApS
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Singh Biotechnology LLC
Sol-Gel Technologies Ltd
Vidac Pharma
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Actinic (Solar) Keratosis reports